Meet our leadership team and executive management
Guido Baechler, President and Chief Executive Officer
Michael Bell, Chief Financial Officer
Peter Heseltine, M.B., B.Ch., B.A.O., Chief Medical Officer
Jeffrey Bishop, Ph.D., Vice President, Research and Development
Anthony Facinelli, Vice President, Clinical Laboratory Testing Services Sales and Marketing
William Hammack, Vice President, Human Resources
Karen Richards, Vice President, Regulatory Affairs and Quality Assurance
Mark Stene, Ph.D., Vice President, Operations
John Todd, Ph.D., Vice President, Clinical Research
Paul Wheeler, Ph.D., Vice President, Life Sciences Sales and Marketing
President and Chief Executive Officer
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.
Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.
Chief Financial Officer
Mike Bell joined Singulex in 2012 and possesses over 20 years of international finance experience gained from a range of strategic, commercial and operational positions. Prior to joining Singulex, Mike held executive and leadership positions at Novartis. Most recently, Mike served as Global Head of Finance, Novartis Diagnostics, responsible for all finance and accounting for this $1B business. Mike also served as Finance Head, Asia Pacific, Middle East, and Africa, Novartis Vaccines, focusing on commercial finance strategies and operations in emerging markets. Prior to Chiron Corporation’s acquisition by Novartis, Mike served as Finance Director for the multinational biotechnology firm. Before joining the healthcare industry, Mike worked for a decade in public accounting with Ernst & Young and Deloitte where he led a wide range of audit and consulting engagements.
Mike received a B.Sc. in Mathematics with Computing from the University of Leicester in the United Kingdom. He is a Fellow of the Institute of Chartered Accountants in England & Wales.
Peter Heseltine, M.B., B.Ch., B.A.O.
Chief Medical Officer
Peter Heseltine joined Singulex in 2014. Peter is a Fellow of the American College of Physicians, National Academy of Clinical Biochemistry, Infectious Diseases Society of America and maintains a position as a Professor of Clinical Medicine at the University of California, Irvine. Nationally, he serves as Chairman, Data Safety Monitoring Board, Intramural Program on Addiction, National Institute of Drug Abuse, NIH and is past Chairman of Division L, American Society for Microbiology. Prior to joining Singulex, Peter served as Senior Vice President and Chief Medical Officer at Prometheus Laboratories where his responsibilities included overseeing clinical trials for oncology therapeutics and in vitro diagnostics validation trials. Previously, Peter held executive positions at Beckman Coulter and Quest Diagnostics Nichols Institute. He was a Professor of Medicine at the University of Southern California and Associate Chairman of Medicine at the Los Angeles County USC Medical Center, co-founding the Rand Schrader HIV/AIDS clinic. Peter has published and presented roughly one hundred peer-reviewed papers.
Peter received his medical training at Trinity College Dublin University and postgraduate training at Yale University, the University of California, Los Angeles, and at the U.S. Centers for Disease Control. He is Board certified in Internal Medicine and Infectious Diseases.
Jeffrey Bishop, Ph.D.
Vice President, Research and Development
Jeff Bishop joined Singulex in 2013. Jeff has worked in the diagnostics industry for more than 13 years at Biosite, Inverness Medical Innovations and Alere. During this time, Jeff held various scientific and leadership positions within the R&D organization including Vice President of R&D for Point of Care platforms and Vice President of R&D for Drugs of Abuse platforms. Jeff has extensive experience working with biomarkers and has led the development of many drug and biomarker assays on numerous platforms across a wide range of disease states.
Jeff earned both an M.S. and a Ph.D. in Bioengineering from the University of California, San Diego and holds a B.S. in Chemical Engineering from Brigham Young University. He also holds an RAC certification in Regulatory Affairs.
Vice President, Clinical Laboratory Testing Services Sales and Marketing
Anthony Facinelli joined Singulex in 2014, bringing with him over 20 years of healthcare management experience, primarily in the clinical laboratory sector. Previously, Anthony held a number of executive positions at Quest Laboratories, most recently as Senior Director of Strategic Alliances- West Region, and as Vice President Sales-West Region, where he was responsible for $1.3B of revenue and over 350 personnel. Anthony also held sales & marketing management positions at PathNet Esoteric Laboratory Institute, Specialty Laboratories, Inc., LabCorp and Unilab. Prior to joining the clinical laboratory sector, Anthony worked in pharmaceutical sales at both Boehringer Mannheim and Pfizer.
Anthony holds a B.S. in Biology from the University of Missouri, Columbia.
Vice President, Human Resources
Bill Hammack joined Singulex with nearly 40 years of global experience in the human resources field. Prior to joining Singulex, Bill held executive positions in human resources for a number of technology companies, including Silicone Image, Komag Inc., General Electric Medical Systems and Diasonics/Elbit Medical Systems. Bill has worked in Europe, Asia and the Middle East. Bill’s experience encompasses creating and managing human resources departments and programs for start-up companies to overseeing human resource activities for multi-national, publicly-traded corporations.
Bill holds a B.A. in Public Policy/Administration from San Diego State University.
Vice President, Regulatory Affairs and Quality Assurance
Karen Richards joined Singulex in 2012. Karen has worked in the in vitro diagnostics industry for over 30 years. She has held executive and leadership positions in Regulatory Affairs, Quality Assurance and Clinical Affairs at Tethys, Celera, Novartis Vaccines & Diagnostics and Beckman Coulter. Karen has led numerous in vitro diagnostics clinical trial programs and regulatory submissions, enabling successful market entry of products into the U.S., Europe, Asia and Latin America. In addition, Karen has built many quality systems in compliance with ISO 9001, 13485, and U.S. Quality System Regulations.
Karen holds a B.A. in Biological Sciences from the University of California, Santa Cruz and an RAC certification in Regulatory Affairs.
Mark Stene, Ph.D.
Vice President, Operations
Mark Stene has over 25 years of experience managing and growing clinical laboratories and operations. Prior to joining Singulex, Mark held a number of key leadership roles at Quest Diagnostics, including Operations Director for the reference laboratories of both the Nichols Institute and Focus Diagnostics and Director of Laboratory Operations for the Southern California Business Unit. Mark also held roles of increasing responsibility in R&D, operations and general management at Endocrine Sciences and the successor companies of Esoterix and LabCorp.
Mark earned a Ph.D. in Experimental Pathology, an M.B.A. and a B.S. in Biochemistry from the University of California, Los Angeles. He is licensed in California as a Clinical Laboratory Scientist (CLS) and holds a Certification of Qualification (COQ) for the State of New York.
John Todd, Ph.D.
Vice President, Clinical Research
John Todd joined Singulex in 2007 and has championed Singulex’s clinical programs to demonstrate the clinical utility of Single Molecule Counting (SMCTM) technology for cardiovascular disease risk prediction and patient management. John has substantial diagnostics development experience, having developed products to address unmet clinical needs in numerous disease areas and successfully establishing their medical advantage. Prior to joining Singulex, John held leadership and executive positions at numerous healthcare companies including Chiron Diagnostics, Bayer Diagnostics, Baxter Healthcare, NUGEN Technologies, Protogene Labs and ENZO Biochem. He has co-authored over 60 peer-reviewed publications and 90 scientific abstracts, been issued 15 patents and presented at over 100 biomedical scientific conferences. John has received 6 SBIR grants for the development and commercialization of diagnostic products.
John received a Ph.D. in Biochemistry and a B.S. in Biology from the University of Southern California, followed by post graduate training in Cell and Molecular Biology at the Sabatini Lab, New York University Medical Center.
Paul Wheeler, Ph.D.
Vice President, Life Sciences Sales and Marketing
Paul Wheeler joined Singulex in 2012 as Director of Life Science Sales for Europe and was promoted to Vice President, Life Science Sales and Marketing in March 2014. Prior to joining Singulex, Paul gained extensive sales and marketing experience with emerging technologies in a number of life science and diagnostics companies. Most recently, he served as Director of European Sales at Gyros AB. Previously, Paul served as Associate Director of International Sales at Oxford Immunotec Ltd, where he was responsible for building a global distribution network for a latent tuberculosis diagnostic, and as Vice President, Global Sales and Marketing at Guava Technologies Inc.
Paul holds a Ph.D. in Transplantation Immunology from the University of Oxford, Queens College, and a 1st Class Honors Degree in Cell and Molecular Biology from Oxford Brookes University.